Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.
Findings from a recent study show that a neutrophil-to-lymphocyte ratio of less than 6 before treatment was correlated with improved overall survival for patients with endometrial cancer.
Results from the second interim analysis of the phase 3 TROPiCS-02 trial showed significantly improved overall survival among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who were given sacituzumab govitecan vs physician’s choice of treatment.
ONCOLOGY Co-Editor-in-Chief Julie M. Vose, MD, MBA, explores high drug costs and financial toxicity.
Hematologist/oncologists provide a broad overview of the pharmacologic agents used to prevent graft vs host disease at their institutions.
Expert panelists elucidate the occurrence of graft vs host disease in patients receiving either stem cell or allogeneic transplantation.
Data from the PARADIGM trial that were presented at 2022 ASCO demonstrated that panitumumab plus FOLFOX should be standard of care for patients with left-sided, RAS wild-type colorectal cancer, according to Tanio S. Bekaii-Saab, MD.
Patients with newly diagnosed acute myeloid leukemia had longer overall survival with a modified dosing schedule of venetoclax plus a hypomethylating agent.
The primary end point of improved progression-free survival was met in the phase 3 DESTINY-Breast02 trial when patients with HER2-positive unresectable and/or metastatic breast cancer were given trastuzumab deruxtecan vs physician’s choice of therapy.
Results from the phase 2 PEMMELA trial revealed positive treatment benefits in patients with malignant pleural mesothelioma who were given pembrolizumab plus lenvatinib.